Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu

Jiamei Chen, Wei Gao, Ping Zhou, Xiaocui Ma, Benjamin Tschudy-Seney, Chenghai Liu, Mark A Zern, Ping Liu, YuYou Duan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY"s role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.

Original languageEnglish (US)
Article number18841
JournalScientific Reports
Volume6
DOIs
StatePublished - Jan 6 2016

Fingerprint

Hepatocytes
Medicine
Wnt Signaling Pathway
MAP Kinase Signaling System
Liver Cirrhosis
Toxicology
Human Embryonic Stem Cells
Albumins
Fibrosis
Pharmacology
Liver
Enzymes
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu. / Chen, Jiamei; Gao, Wei; Zhou, Ping; Ma, Xiaocui; Tschudy-Seney, Benjamin; Liu, Chenghai; Zern, Mark A; Liu, Ping; Duan, YuYou.

In: Scientific Reports, Vol. 6, 18841, 06.01.2016.

Research output: Contribution to journalArticle

Chen, Jiamei ; Gao, Wei ; Zhou, Ping ; Ma, Xiaocui ; Tschudy-Seney, Benjamin ; Liu, Chenghai ; Zern, Mark A ; Liu, Ping ; Duan, YuYou. / Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu. In: Scientific Reports. 2016 ; Vol. 6.
@article{7423846d069b48f4b0f2d5399da6abbe,
title = "Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu",
abstract = "Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY{"}s role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.",
author = "Jiamei Chen and Wei Gao and Ping Zhou and Xiaocui Ma and Benjamin Tschudy-Seney and Chenghai Liu and Zern, {Mark A} and Ping Liu and YuYou Duan",
year = "2016",
month = "1",
day = "6",
doi = "10.1038/srep18841",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu

AU - Chen, Jiamei

AU - Gao, Wei

AU - Zhou, Ping

AU - Ma, Xiaocui

AU - Tschudy-Seney, Benjamin

AU - Liu, Chenghai

AU - Zern, Mark A

AU - Liu, Ping

AU - Duan, YuYou

PY - 2016/1/6

Y1 - 2016/1/6

N2 - Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY"s role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.

AB - Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY"s role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.

UR - http://www.scopus.com/inward/record.url?scp=84954562262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954562262&partnerID=8YFLogxK

U2 - 10.1038/srep18841

DO - 10.1038/srep18841

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 18841

ER -